Alex Janin is a Reporter at various esteemed publications, including The Wall Street Journal and Yahoo Finance. He specializes in themes such as science, natural sciences, and healthcare, focusing on diagnostics and their implications in the medical field. Alex's work has been featured in notable outlets like The Epoch Times, LiveMint, Yahoo News, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Alex Janin's articles predominantly focus on health-related topics, particularly those related to aging and exercise. His work often cites data and includes seasonal content. When reaching out to Alex, consider providing access to credible data or studies that support your pitch.
Given the thematic coverage of his articles, experts in gerontology, exercise physiology, public health or healthcare professionals with knowledge of trends related to aging and exercise may find success in pitching story ideas. Keep in mind that his geographic focus is national (United Kingdom).
This information evolves through artificial intelligence and human feedback. Improve this profile .
While hacks have raised safety alarms, researchers said their experiment could protect against drug-resistant bacteria and save lives.
By: Alex Janin, Sara Ashley O'Brien
Biohackers, longevity enthusiasts and alternative medicine doctors want the peptide BPC-157. Now compounders may be one step closer to lawfully providing it.
Patients, doctors and nurses are turning to the technology for help identifying rare and undiagnosed diseases.
Patients with rare diseases often spend five years or more searching for a diagnosis. Now artificial intelligence is helping some get answers faster.
By: Alex Janin, Xavier Martinez
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late-stage trial at preventing m
By: Alex Janin
The day after Moderna’s stock posted its biggest one-day gain on record, it is on track for its largest percent drop in more than two years as investors digested the news and adjusted their positions. Prior to Wednesday’s rally on [positive mRNA cancer vaccine data](https://www.wsj/health/pharm
By: Xavier Martinez, Alex Janin
After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.
By: Alex Janin, Xavier Martinez
CAMBRIDGE, Mass.—At 11 a.m. on Wednesday, Moderna's 4,500 employees stopped working. Meetings were canceled, workers stepped off production floors.
Patients, doctors and nurses are turning to the technology for help identifying rare and undiagnosed diseases
